Kimball Carr
appointed Kimball Carr, our current Chief Executive Officer, as Chairman of the Board
Highest-materiality recent filing
Inspire Veterinary Partners delisted from Nasdaq, now trades on OTCQB under IVPR
Nasdaq denied Company's request to continue listing; common stock suspended from Nasdaq on Jan 21, 2026.
Inspire Veterinary issues $975K convertible note at 23% OID, 10% interest; director resigns
Issued $975K principal secured convertible note to Manetto Hill Fund for $750K; 10% interest, matures Dec 31, 2026.
Inspire Veterinary lowers Series B floor price to $0.05, redeems 2,027 shares for $2.7M
Floor price reduced from $0.1879 to $0.05 per share for Series B Preferred Stock.
Inspire Veterinary Partners gets Nasdaq hearing date for delisting appeal on Jan 13, 2026
Previously reported non-compliance with Nasdaq minimum bid price rule (bid <$1 for 30 consecutive days).
Inspire Veterinary Partners receives Nasdaq delisting notice; suspension set for Nov 24, 2025
Received delisting notice from Nasdaq on Nov 13, 2025 for failing minimum bid price requirement.
Inspire Veterinary issues $357k convertible notes at 30% OID to two investors
Issued two Senior Convertible Promissory Notes, each $178,571 principal, to Keystone Capital Partners and Seven Knots at 30% OID, netting $250k.
Inspire Veterinary dismisses auditor Kreit & Chiu; going concern, material weaknesses cited
Dismissed Kreit & Chiu CPA LLP as independent auditor on October 16, 2025; no disagreements occurred.
Inspire Veterinary Partners sells 1,253 Series B preferred shares for $1.0M gross proceeds
Amended July 28 SPA to add new institutional investors, including KCP Fund I, LLC.
Inspire Veterinary believes it regained Nasdaq equity compliance via $5M preferred stock sale
Company received Nasdaq deficiency notice on Apr 10, 2025 for stockholders' equity of $1.56M, below minimum requirement.
Inspire Veterinary Partners raises up to $10M via Series B convertible preferred stock
First closing generated ~$5M in cash and transferred securities; up to $4M additional at investor option.
Inspire Veterinary Partners acquires Debary Animal Clinic for ~$2.06M; adds ~$1.8M annual revenue
Total consideration: $925k for clinic assets ($832.5k cash + 54,734 restricted shares) and $1.132M cash for real estate.
Inspire Veterinary Partners issues $296,700 of convertible notes at 75% market conversion
$204,700 note issued to 1800 Diagonal Lending LLC with $24,564 interest, matures March 30, 2026.
Inspire promotes Lynley Kees to CPO; YTD DVM hiring up 500%; acquires Debary Animal Clinic for $925K
Lynley Kees promoted from VP of HR to Chief People Officer, effective April 28, 2025; base salary $235K.
Inspire Veterinary Partners receives Nasdaq delisting notice for minimum equity deficiency
Nasdaq notified Inspire of non-compliance with minimum stockholders' equity requirement; equity reported as $1,562,005.
Inspire Veterinary raises $2.0M in registered direct offering; warrants could add $4.0M
Gross proceeds of $2.0M from sale of 1,092,896 shares (or pre-funded warrants) at $1.83/unit.
Reverse stock split effective Jan 27, 2025 at 1:25 ratio; shares will trade on split-adjusted basis under symbol IVP.
Inspire Veterinary Partners approves 1-for-25 reverse stock split to regain Nasdaq compliance
Reverse split effective Jan 3, 2025, converting every 25 shares into 1 share.
Inspire Veterinary Partners enters $25M ATM stock offering with H.C. Wainwright
Up to $25M in common stock may be sold at market through H.C. Wainwright as sales agent.
Inspire Veterinary faces Nasdaq bid price non-compliance; gets public reprimand for prior offering
Demonstrated compliance with Nasdaq minimum equity rule; subject to Mandatory Panel Monitor until Dec 12, 2025.
Inspire Veterinary Partners cuts warrant exercise price to $0.20 for 2.5M shares
Reduced exercise price of 2,500,000 warrants from $1.00 to $0.20 effective Oct 8, 2024.
Nasdaq Staff Determines Inspire Veterinary Failed Rule 5635(d); Faces Delisting
Staff letter dated Sep 24, 2024, says July 15 'best efforts' offering didn't qualify as public offering.
Inspire Veterinary closes $6M public offering of units with warrants
Gross proceeds of ~$6M from sale of 6M units at $1.00/unit; each unit includes a share or pre-funded warrant plus a warrant.
Nasdaq grants Inspire Veterinary Partners continued listing until Sept 4, 2024 with conditions
Company must file registration statement by June 15, 2024 for a public offering led by Spartan Capital Securities.
appointed Kimball Carr, our current Chief Executive Officer, as Chairman of the Board
Max materiality 0.90 · Median 0.60 · Most common event other_material